Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05102786
Other study ID # CSD210904
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 26, 2021
Est. completion date March 8, 2022

Study information

Verified date June 2022
Source RAI Services Company
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S. The purpose of this Actual Use Study (AUS) is to investigate how U.S. adult tobacco consumers 21 to 60 years of age, inclusive, who typically smoke on average (≥5 cigarettes/day) on at least 20 out of the past 30 days will use a heated tobacco product comprising a heating device and four non-combusted cigarette variants (HTP Investigational Product [IP]) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environment and in the context of typical consumer marketing materials.


Description:

Adult smokers will be recruited, and candidate subjects who meet study inclusion criteria and none of the exclusion criteria will give verbal consent for further screening. Candidate subjects will be scheduled to attend an in-person Site Enrollment Visit. Subjects will self-report their ad libitum use of the HTP IP as well as use of combustible cigarettes (CCs) and any other tobacco- or nicotine-containing products (TNPs) on a daily basis using an electronic diary (eDiary). During a 1-week Baseline Assessment Period (BAP), enrolled subjects will record all CC and any other TNP use in the eDiary. At the end of the BAP, subjects will return to the study site for Site Visit 1 (SV1). At this visit, subjects will be provided the HTP IP for the first two weeks of the AUP. During the subsequent 6-week observational AUP, subjects can choose to use the HTP IP (or not). Subjects will be instructed to record all daily TNP and CC use in the eDiary. They will return to the site every two weeks during the AUP for an in-person interview, to complete questionnaires and for product accountability and resupply. As with SV1, at Site Visit 2 and 3, subjects will be able to select their preferred HTP IP variants (if desired) for use during the subsequent 2-week AUP. Point of sale materials will be present during subject interactions at SVs. After Week 6 of the AUP, there will be a final site visit and week-long Close Out Period. In addition to collecting information on daily ad libitum use of HTP IP, TNP and CC use, the study will assess subjective measures for each HTP IP, including product use/misuse and intent to use again (at close of study). Information on intention to quit CC use will be collected at enrollment and at study conclusion. A passive surveillance mechanism will be used to collect information on adverse health experiences.


Recruitment information / eligibility

Status Completed
Enrollment 1180
Est. completion date March 8, 2022
Est. primary completion date March 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria: 1. Adult males or females, 21-60 years old, inclusive, verified with government-issued photo ID. 2. Must be a current smoker of factory-made filtered menthol and/or non-menthol cigarettes, has smoked at least 100 cigarettes in their lifetime, and typically smoke on at least 20 days out of the past 30 days. 3. Smokes, on average, = 5 combustible cigarettes per day (CPD) on days when cigarettes are smoked. 4. Must indicate "an intention to use" the HTP IP after a brief review of product information at the Screening and Enrollment Visit (SEV). Subjects will not try the product at the SEV. 5. Available and interested in participating in an 8-week study about the HTP IP. 6. Able and willing to comply with all study requirements, including questionnaires, the eDiary reporting procedures, and provide valid contact information. 7. Able to read, understand, and willing to sign Informed Consent Forms (ICFs) and complete questionnaires written in English. 8. Has not participated in any tobacco-, vapor-, or nicotine-related research within 3 months of screening. Exclusion Criteria: 1. Self-reports as currently quitting or intending to quit within the next 3 months all tobacco or nicotine product use ("currently" is defined as within (=) 30 days prior to signing ICF#1). Those who intend to quit CC only can be enrolled. 2. Female subjects who are currently pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report. 3. Female subjects who self-report they are not using adequate methods to prevent pregnancy. 4. Self-reports "poor" physical health (based on the five-category Population Assessment of Tobacco and Health (PATH) questionnaire): "In general, how would you rate your physical health?" (Response choices: Excellent, Very Good, Good, Fair, Poor). 5. Self-reports "poor" mental health (based on the five-category PATH questionnaire): "In general, how would you rate your mental health?" (Response choices: Excellent, Very Good, Good, Fair, Poor). 6. Employees of tobacco or vapor companies.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
40007388
A non-combusted cigarette used with heated tobacco device 20020064
40007385
A non-combusted cigarette used with heated tobacco device 20020064
40007387
A non-combusted cigarette used with heated tobacco device 20020064
40007386
A non-combusted cigarette used with heated tobacco device 20020064

Locations

Country Name City State
United States Schlesinger Atlanta Atlanta Georgia
United States Schlesinger Baltimore Baltimore Maryland
United States Schlesinger Charlotte Charlotte North Carolina
United States Schlesinger Chicago Chicago Illinois
United States Schlesinger Dallas Dallas Texas
United States Schlesinger Minneapolis Edina Minnesota
United States Schlesinger Houston Houston Texas
United States Schlesinger Kansas City Kansas City Missouri
United States Schlesinger Nashville Nashville Tennessee
United States Schlesinger St. Louis Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
RAI Services Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and Proportion of Established Users Number and proportion of subjects who meet the definition of "established users" of the HTP IP 6 weeks
Primary Number and Proportion of Established Users who reduce their CPD consumption Number and proportion of subjects among "established users" of the HTP IP who reduce their CPD consumption by at least 50% 8 weeks
Primary Descriptive weekly average CPD consumption Descriptive weekly average CPD consumption per subject among all subjects who complete the study, including both established and non-established users of the HTP IP 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Active, not recruiting NCT02752022 - Monitoring the Transition From Smoking to E-cigarettes
Completed NCT02901171 - The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT04340830 - The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants N/A
Completed NCT02949648 - Electronic Cigarette Use and Quitting in Youth N/A
Completed NCT02246114 - Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors N/A
Completed NCT01954407 - Young Adults' Responses to Anti-smoking Messages N/A
Completed NCT01898507 - Nicotine Metabolism and Low Nicotine Cigarettes N/A